After several years of courtroom squabbling, a federal court judge ruled that Novartis (NVS) must face trial in a case brought by the federal government and more than two dozen states, alleging the drug maker violated kickback laws by paying doctors to prescribe some of its medicines.

In his order, U.S. District Court Judge Paul Gardephe concluded the federal government provided sufficient evidence of a “company-wide kickback scheme,” but does not have to prove a direct “quid pro quo” agreement between Novartis and doctors for the company to be liable under the False Claims Act. The drug maker was accused of paying doctors speaking fees to inappropriately boost prescribing that led to false claims submitted to Medicare and Medicaid.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy